

Index

Note: To allow faster and more comprehensive searches, an electronic version of the index will be available on our website (www.fanconi.org).

- acute myelogenous leukemia (AML), 14, 16-18, 38-39, 42-43, 45-51, 53, 60, 71, 176, 198, 228, 270, 289, 291-293, 298, 300, 304-305, 373, 382
- adenoma, see *hepatic*
- adrenal insufficiency, 157, 159, 161
- adrenocorticotrophic hormone (ACTH), 150, 161-162
- adult FA patient, 295-306; gynecologic and fertility issues, 300; bone marrow transplant, 299; psychosocial issues, 302; solid tumors in, 298-299; transition from pediatric to adult-oriented care, 300
- agranulocytosis, 66
- alanine transaminase (ALT), 65-66, 86, 88-91, 382
- albumin, 90
- alcohol, risks from use, 2, 4, 14, 90, 93, 205-206, 218, 227, 251, 271-274, 283, 293, 298, 302, 343, 345
- Alexander Graham Bell Association for the Deaf and Hard of Hearing, 192
- alkaline phosphatase (ALP), 90, 382
- allergies, 226
- alternative medicine, 95
- American Academy of Audiology, 193, 195
- American Academy of Otolaryngology, 193
- American Diabetes Association, 377
- American Society of Blood and Marrow Transplantation, 245, 255
- American Speech-Language-Hearing Association, 193
- amniocentesis, 18, 324, 371
- anal atresia, see *anus*

- androgens, 14, 53-56, 58-60, 62, 67, 72, 87-88, 91, 97, 129, 147, 153, 169, 171, 223, 226, 238, 290, 336, 376, 379, 382; androgen-responsive “acquired” aplastic anemia, 17; danazol, 55-56, 67, 72, 354; effect of androgens on: endocrine function, 169, glucose metabolism, 151, 154, growth, 54, insulin resistance 132, 153-154, 156, 167, 170-171, 250, lipids, 132, liver, 54, 376, 87-91, masculinizing side effects of, 55; menses, 381; oxymetholone, 54-56, 67; pregnancy, use during, 129; risks and side effects of, 54; transplant, use prior to, 59-61
- anemia, 1, 3, 5-6, 10, 14, 17, 21-27, 33, 35, 41-45, 48-49, 55, 57, 60-62, 66, 68-74, 96-99, 121, 123, 133, 139-141, 144, 167, 171-173, 175-177, 179, 192, 194-196, 198, 202-203, 217, 219, 221, 223, 225, 230, 239-240, 242-246, 255-259, 267-272, 282, 284-288, 294-295, 298, 300, 304-305, 307, 310, 312, 314-316, 319, 327-331, 333, 336, 341, 344, 350-352, 367-369, 375, 382-383, 386, 394-398; aplastic, 14, 17, 33, 43, 48-49, 55, 72-73, 98, 177, 221, 223, 225, 230, 239, 243, 245, 285, 298, 382-383
- anesthesia, see *pain*
- anus, 75, 77, 308, 382, anal atresia, 102; anorectal malformations, 75-77; ectopic, 19; imperforate, 20
- aplastic anemia, see *anemia*
- appetite, 74, 83-85, 96, 150; glucocorticoids, effect on, 170; stimulants, 85, 88, 96, 99; supplemental feeding, 83-85, 91, 95
- arm lengthening, see *forearm lengthening*
- arthritis, 66, 300
- aseptic necrosis of bone or joints, see *avascular necrosis*
- aspartate transaminase (AST), 86, 88-91, 383
- asthma, 228
- autosomal recessive inheritance, see *genetic counseling*
- avascular necrosis, 56, 250
- azoospermic, 300
- bacteremia, 379
- beta cell dysfunction, 171
- biliary, 90, bilirubin, 88, 90, 369
- bladder abnormalities, 228, 369

- bleeding, 43, 56-57, 60, 63-64, 67, 77, 79, 84, 88, 91, 95, 123, 129, 133-135, 163, 188, 203, 213, 216, 228, 353; from duodenal intubation, 79; from fish oil (omega-3 fatty acid), 95; from ginkgo, 228; from hepatic adenoma, 56, 88; excessive menstrual bleeding, 123, 129, 133; mucosal, 67, 133; oral, 203, 213, 215-16; risk from drugs such as aspirin or ibuprofen, 67; side effect of cyclosporine A/tacrolimus, 233; menstrual, 123, 129, 133
- blind loop syndrome, 77
- blood counts, 45-49, 51-54, 59, 107, 169, 227, 297, 354, 369, 376; post-transplant, 374; to monitor bone marrow failure, 45, 49-52
- body mass index, 81-82, 124, 150, 153, 383
- bone age, 147-148, 163, 169
- bone marrow, 6, 11, 13, 16-18, 21, 26-27, 32-33, 35, 37-40, 42-54, 56-59, 61-63, 66-73, 80, 96, 98, 124, 133, 142, 154, 172, 174, 177-178, 188, 198, 202, 212, 215-216, 222-223, 225, 228-230, 238-244, 250, 255-258, 261-263, 266, 268-270, 273, 279-280, 284-286, 290-291, 294, 296, 299, 304-305, 315-316, 323, 353-354, 362, 364-367, 369, 372-373, 379, 382-390, 392; aplasia, 298, 373; aspiration, biopsy, 45-52, 57, 198, 237, 369, 373; cellularity, 45-46, 49, 53; clinical monitoring and management of failure, 49-52, 373; clonal abnormalities, see *clones*, *cytogenetic clonal abnormalities*; dysfunction, 43-52, 215-216; dysplasia, 45-46, 50, see also *myelodysplasia*; examination, 46, 49-51, 68, 374; onset of anemia, 61-62, 315; severity of failure, 49; suppression of, secondary to H2-antagonists, 80; suppression of, 51; transplant, see *transplant*; treatment options for failure, 52-61, 259-262
- bone mineral density, see *osteopenia*, *osteoporosis*
- bowel, 78-80, 391; antegrade continence enema (ACE) 78; constipation, 78-79, 234; encopresis, 78, 403, 407; fecal incontinence, 78; malabsorption, 82; obstruction, 80; small bowel overgrowth, 78-79
- breast cancer susceptibility genes, 319
- bronchitis, 228
- BUN (blood urea nitrogen test), 254
- Busulfan, 177-178, 223, 239, 384
- café au lait* spots, 17, 101, 228, 384
- cancer, 2-3, 5, 7-8, 14, 16, 18, 22, 24, 26, 34, 37-38, 41-44, 69-73, 77, 85-86, 90, 94-98, 123-132, 135, 139-142, 160, 171-173, 175-176, 195-196, 198-202, 205-207, 209, 211, 213, 215-218, 220, 224, 227, 237-238, 241-243,

- 245, 255-258, 261-263, 265, 268, 270-273, 275, 277-278, 281, 283-294, 297-299, 304-308, 313, 315, 319-323, 326, 328-332, 343-345, 350-351, 353, 369-370, 372, 378-383, 385, 389-391, 394, 396, 399-400; family history of, 84, 308, 369; risk of, 94, 321-323, 326, 330, 370, 404; secondary, 300-301; surveillance for, 3, 14, 128, 251, 275-276, 297-298, 313, 372, 378-380
- cancer, types of, acute lymphocytic (lymphoid) leukemia, 145; acute myelogenous leukemia (AML), 14, 16-18, 38-39, 42-43, 45-51, 53, 60, 71, 176, 198, 228, 270, 289, 291-293, 298, 300, 304-305, 373, 382; astrocytoma, 314; bladder, 289; brain, 20, 287-293; breast, 2, 7, 123, 128-129, 131, 135-136-224, 287-291, 299, 308, 319-323, 379-380; breast, male, 308, 319, 321; cervical, 20, 125-127, 136; colon, 289; dermatofibroma, 289; esophageal, 18, 20, 86-87, 204, 275, 287; gastrointestinal, 86, 308; genitourinary, 273-274; gynecological, 2, 18, 128, 136, 160, 273, 380-381; head and neck squamous cell carcinoma, *see head and neck squamous cell carcinoma*; human papillomavirus (HPV)- associated, 18, 124-127, 136- 238, 271-274, 293, 298, 379; kidney, *see cancer; renal*; liver (hepatocellular), 18, 54, 56, 87-88, 90, 93, 287, 290-291; lung, 289-291; lymphoma, 45, 289; medulloblastoma, 16, 20, 34, 314; melanoma, 196, 199, 201, 228, 320; neuroblastoma, 20, 287, 290-293; osteosarcoma, 289; ovarian, 7-8, 127, 132, 298, 308, 319-323; pancreatic, 8, 319, 322; prostate, 308, 319, 321-322; renal, 287, 290; retinoblastoma, 20, 273, 289; skin, 196, 198-208, 248, 254, 380; stomach, 289-291; vaginal, 16, 20, 125, 379; vulvar, 16, 20, 125-127, 136, 228, 287, 298, 379; Wilms tumor, 16, 17, 20, 34, 287, 292-293, 314, *see also renal*
- carcinogens, to avoid, 4, 271, 293
- cardiac, 62-64, 66, 76, 248, 380, 392, arrhythmias, 63, 66; cardiac iron toxicity, 62-66; cardiac siderosis, 62; cardiovascular disease, 86, 131-132, 380; function, 62, 65-66; toxicity, 63, 65-66; transplant, late complication, 248, 252
- cardiopulmonary, congenital defects, 19
- cardiovascular, 86, 131-132, 173, 256-257, 380, vascular disease, 380
- carpometacarpal 103, 106
- carriers, 2, 140-141, 299, 307-308, 312, 318-323, 330, 339, 384, 391, cancer risk in, 2, 15, 299, 307, 319-323; risk of FA in each pregnancy, 310; testing, 316-319
- Center for International Blood and Marrow Transplant Research, 222, 239, 245, 255, 384

- Centers of Excellence, 226
- central venous catheter, 83
- cervical esophagus, 275
- cetuximab, see *erbitux*
- chest x-ray, 276
- Children's Oncology Group, 169, 245, 255
- chimerism, 250
- cholestasis, 91-92, 249, 281
- cholestatic jaundice, 88
- chorionic villus sampling, 18, 324
- chromosomal breakage or fragility test, 12, 29-32, 101, 324, 371; confirmatory FA diagnosis prior to HSCT, 59-60, 229, 237; see also *diagnosis of FA*
- cirrhosis, 62-63, 88, 92-93, 375
- cisplatin, 280
- clinical management checklist, 367
- clinical trials, 3, 94, 98, 202, 256, 259, 265, 267, 279, 375
- clones, 39, 42, 47-48, 51, 270, 305, cytogenetic clonal abnormalities, 51; significance of clone, 37-40, 47-50
- colony stimulating factors, see *hematopoietic growth factors*
- colposcopy, 127, 379, 385
- comparative genomic hybridization (CGH), 36, 47, 312
- Complementary and Alternative Medicine of the National Institutes of Health, Office of, 95
- complementation groups, , 11, 23, 29, 146, 385; genotype-phenotype correlations, 2, 12, 15-17, 34; relative frequency of, 10; testing for, 11-12
- consanguinity, 369
- constipation, 67, 78-79
- contraception, hormonal, 124, 164, 379
- corticosteroids, 147, 153, 166, 375
- cortisol sufficiency, see *endocrine system*

- cough, 77
- creatinine, 369
- cryptorchidism, 161, 164
- cryptosporidia antigen, 79
- cytokine therapy, see *colony stimulating factors*
- cytopenia, 43, 45-46, 49, 224, 281, 316, 385; androgen treatment for, 53-56
- D2 Western Blot, see *FANCD2 Western Blot*
- danazol, see *androgens*
- deafness, 190, 193
- dental 8, 191, 203-204, 206-209, 211-213, 216-218, 228, 238, 248, 257, 274-275, 282, 299, 378, caries due to chronic GvHD, 204; gingivitis, 203, non-alcohol mouthwash, use of, 205-206; oral hygiene, 203; orthodontic treatment, 211; periodontitis, 203; pre-transplant examination, 215-216; surveillance for oral cancer, 209-210
- dermatology, 397; basal cell carcinoma, 196, 198-199; *café au lait* spots, 197; cutaneous (skin) GvHD, 200-201; darkening of skin, 197; dermatology exams post-transplant, 196; dry skin, 246; fibroblasts, 317; hyperpigmentation, 17; hypopigmentation, 17; melanoma, 199-200, 201, 228, 320; nevi, 199, 228, 248, 254, 380; rash, 161, 231, 233-234, 280; squamous cell carcinoma, 198-199; sun exposure effect on, 196, 197, 200; Sweet's syndrome, 196-198, 392, 406, 418
- diabetes, 63, 86, 93, 144, 153-154, 156, 160, 169, 172, 204, 206, 250, 256, 300, 377, 381, 388; abnormal glucose or insulin metabolism in, 153-155; adult care for, 167; complication of obesity, 154; insulin therapy for during HSCT, 155; insulinemia, 155; post-transplant, 246, 250; risk of metabolic syndrome, 156; treatment of, 155
- diagnosis of FA, 3-14, 17-18, 27, 29, 32, 37, 44-45, 53, 75-76, 197-198, 291, 297-298, 313, 333, 335, 346, 350, 362; examples of anomalies, 19-20; index of suspicion, 17-20; indications for testing, 19-20; laboratory tests to diagnose, 27-40; testing siblings, see *siblings*
- diarrhea, 74, 78-79, 82, 84, 91, 228, 376
- diet, 85-86, 90-91, 95, 156, 200, 211, 251, 377, dietary record, 82, counseling, 80, 82-83, 86; dietary supplements, 83; nutrition, supplemental, 83-85, 91, 95; nutrition, see *nutrition*; obesity, overweight, see *obesity, overweight*;

- underweight, 82, 86, 147, 150, 406, 409, 415, 420-421, weight loss diet, 85-86
- DNA damage response pathway, 6-9
- drugs, see *medications*
- duodenal, 75, 77, 79, 96, 226, 386; duodenal atresia, 75, 77, 226; duodenal intubation, 79
- DXA scan, see *osteopenia, osteoporosis*
- dyslipidemia, 156, 250, 386
- dysphagia, 210, 275, 279
- ear, 179-181, 183-184, 186-192, 195, 210, 370, 376, absent ear canal (aural atresia), 181, 183, 188; anatomy and function of, 179-181; cochlea, 180-181, 190; ear canal, 180-181, 183, 187-190; ear malformations, 183; eardrum, 179-181, 183-184, 188-189, 192, 376; inner ear, 180; middle ear, 180; outer ear, 179
- ear and hearing abnormalities in FA, 183, 191
- education, 128, 184-186, 194-196, 245, 258, 297, 301, 303-304, 334, 342, 347, 376
- elbow, 100, 113, 116
- encopresis, 78
- endocrine system, 3, 144, 250, 386; androgen use, 147-148, 153-154, 157, 169; effect of, see *androgens*; bone mineral density, see *osteopenia, osteoporosis*; cortisol sufficiency, 161; diabetes, see *diabetes*; dyslipidemia, see *dyslipidemia*; endocrine issues in adults, 167; endocrine screening, 149, 407; endocrinopathies in children and adolescents, 407; glucose abnormalities, see *glucose abnormalities*; growth hormone deficiency, see *growth*; height, see *height*; hematopoietic stem cell transplant (HSCT), 169-170; hyperglycemia, see *hyperglycemia*; hypothyroidism, see *thyroid*; insulin, abnormal metabolism of, see *insulin*; medications and treatments that affect endocrine function, 169-170; multiple hormonal deficiencies, effect on pituitary-hypothalamus, 161-162; multiple transfusion therapy, effect on, 169; puberty, effect on, see *puberty*
- endometrium, 135
- endoscopy, 80, 84, 91
- epiphyseal closure, epiphyses, 54, 169

- erbitux, 280-281, 299
- erythrocyte sedimentation rate, 79
- erythroplakia, 386
- esophageal, 18, 75-76, 86-87, 96, 167, 204, 217, 275, 279, 286-287, 386;
 atresia, 75-77, 102; bleeding, 77; gastroesophageal reflux, see *reflux*; reflux,
 see *reflux*
- esophagus, 75-77, 87, 273, 275, 279, 290-291, 386, 392, 405, 408, cervical,
 275, 405
- ethnic background, examples of FA populations, 308, 311
- European Fanconi Anemia Research Group, 41, 329
- European Group for Blood and Marrow Transplantation (EBMT), 245
- exercise, 86, 156, 173, 251, 348
- eyes, 17, 88, 248, 345, 353, dry, 233, 246, 248, 374; epicanthal folds, 19;
 keratoconjunctivitis, 248; Sicca Syndrome, 246, 248
- FANCC IVS4*, 15-17, 33, 34, 146, 309, 315
- FANCD2* Western Blot, 12, 370
- fecal incontinence, 78
- fertility, infertility, 18, 124, 129-131, 135, 144, 164, 240, 300, 308, 323, 353,
 373, 379, 381 389; adult, 300; affected by HSCT, 231, 246, preservation,
 130-131, 164, 325
- fever, 64, 67, 197
- fibroblasts, 11, 14, 18, 32, 317, 368
- fibroids, endometrial, 133
- finger, index, 102, 105-109, 116, 121, 391
- flow cytometry, 11, 41, 368, 387
- fluid retention, 234
- fluorescent *in situ* hybridization (FISH), 38-40, 47
- fluoride treatment, 205, 206, 282
- folate deficiency, 83
- forearm lengthening, 119; distraction osteogenesis, 119; wrist fusion, 7, 119-
 120

- Founder effect or mutation, 6, 17, 342; different founder populations, 309
- fructosamine levels, 154
- FSH (follicle-stimulating hormone), 150, 163, 250, 254, 387
- galactorrhea, 170
- gallbladder disease, 78
- gastroesophageal reflux (GER), see *reflux*
- gastrointestinal, 65-66, 74-75, 77-81, 84, 86, 91, 96-97, 134, 197, 240, 249, 308, 367, 376, 387; anal atresia, see *anus*; appetite stimulants, see *underweight*; duodenal atresia, see *duodenal*; esophageal atresia, 75-76, 96, 386, 409, gastric emptying, 77-78, 80-81, 85; gastritis, 80; gastroesophageal reflux, see *reflux*; gastrointestinal symptoms, 78-81; gastrointestinal tract anatomic abnormalities, 75-78; liver disease, see *hepatic*; nutrition as therapy, see *medications*; nutrition, supplemental, see *nutrition*; obesity and overweight, see *obesity and overweight*; peptic disorders, 80, 409, 416; tracheoesophageal fistula, see *tracheoesophageal fistula*
- gastrostomy tube, 83-84, 91
- genes 1-2, 6-8, 10-12, 16-17, 28, 31, 33-37, 44, 128, 132, 238, 241, 260-261, 264-266, 274, 290, 292-293, 308, 311-316, 318-319, 322, 327-328, 354, 366, 385, 388-389, 393, and gene products (proteins), 8, 10; *FANCA*, 6-8, 12, 16, 28, 34, 36, 42, 44, 164, 176, 265-266, 286, 305, 312-313, 315-316, 318, 327-328, 385; *FANCB*, 13, 25, 310, 385; *FANCC*, 6, 16, 24, 33, 42, 44, 146, 164, 265, 269, 313, 315-316, 322-323, 327; *FANCD1 (BRCA2)*, 8; *FANCD2*, 8, 12, 23, 33, 316, 328, 370; *FANCE*, 8; *FANCF*, 25, 312; *FANCGXRCC9*, 8; *FANCI (KIAA1794)*, 8; *FANCI (BACH1, BRIP1)*, 8; *FANCL (PHF9/POG)*, 8; *FANCM (hef)*, 8; *FANCN (PALB2)*, 8, *FANCO (RAD51C)*, 8, *FANCP (SLX4)*, 8, *FANCO (ERCC4)*, 8
- gene therapy, 3, 238, 259-261, 264-270, 362, 371, 387, 391; stem cell gene therapy, 264-266; stem cell therapy, 262-264
- genetic counseling, 3, 13, 15, 33, 59, 307, 318, 326, 370-371; autosomal recessive inheritance, 7, 9, 310, 317; genetic testing, 311-313, see also *mutation analysis* and *complementation groups*; mode of inheritance, 310-311; reproductive issues, 323-324
- genital warts, 124-125, 127, 274
- genotype-phenotype correlations, see *complementation groups*
- giardia antigen, 79

ginkgo, 228

glomerular filtration rate (GFR), 237

glucocorticoids, 160, 165, 171

glucose abnormalities, 153-155; in adults, 156, 167; during or post-HSCT, 169, 234; glucose intolerance assessment and monitoring, 154; incidence of in FA, 153; medications known to alter glucose metabolism, 155

gonads, 55, 130; Cytosan, effect on, 170; gonadal function, 149, gonadal abnormalities, 19, 63, 124, 130, 144, 148-149, 152, 161-164, 166-168, 170; hypogonadism, see *gonadal abnormalities*, 63, 124, 144, 148, 161-164, 166-168, 170-171, 176; effect of iron overload on, 149, 164; fertility, 164; HSCT effect on, 246, 250, 374; puberty, 162-163

graft-versus-host disease, 18, 53, 62, 91, 98, 126, 134, 140, 178, 200, 202, 240-241, 246, 248, 256-257, 263, 273, 285, 297, 387

grieving process, 349, 352-354, 357, 359-360, 366; and the physician's role, 361-366; physical changes due to, 359

growth, 45, 54, 57, 62-63, 74, 76, 81-83, 85, 90, 96, 99, 101, 111, 114, 118-119, 124, 144-149, 153, 157-161, 163, 166, 168-169, 171-178, 188, 200, 223, 229, 238, 245, 248, 250, 254, 256-257, 263-265, 280, 286, 342-343, 370, 377, 387, 390; androgen therapy effect on, 147, 148, 169; cortisol sufficiency, 149; hemoglobin level necessary for, 149, 154; hormone deficiency, 145; hormone, screening for, 149; iron overload, 153; pubertal delay, effect on, 153; radiation, effect on, 147, 159, 162, 169-171; rate and bone maturation, 147-148

growth plate, see *epiphyseal closure*

gynecologic and fertility issues in females, 123-137; cancer, see *cancer* for specific type; cervical cytology testing, 127, 136; fertility, see *fertility*; genital tract malformations, 164; gynecologic cancer, see *cancer, types of, gynecological*; gynecological issues related to HSCT, 133-135; human papillomavirus, see *cancer, types of, HPV-associated*; vaccination/immunization; mammograms, see *mammography*; menopause, see *menopause*; menses, 381; osteoporosis, see *osteopenia/osteoporosis*; pregnancy, see *pregnancy*; puberty, see *puberty*; uterine polyps, 410, vulvar cancer, 16, 20, 125-127, 136, 287, 298, 379

H2-antagonists, 80

hair, 163, 181, 200-201, facial, 54; pubic, 163, 166; scalp, 54

- hand and arm differences, 99-122
- head and neck squamous cell carcinoma (HNSCC), 16, 18, 71, 206, 217, 243, 284-286, 271-282, 291, 293, 299, 305, 378; age of presentation, 272, 275; chemotherapy treatment of, 280-282; diagnosis and evaluation, 275-276; frequency of in FA, 272-273; human papillomavirus, 272, see *vaccination/immunizations*; testing for FA in, 272; prevention of, 273-275; radiation treatment of, 278-279; surgical treatment of, 278; surveillance for, 275-276; tobacco and alcohol use risks, see *smoking; alcohol*; T-stage, 276
- hearing and ear abnormalities, 179, 191; hearing and ear screening, 185
- hearing loss, 179, 181-195, 248, 370, 376, amplification systems, 179, 186-187, 192, 376; diagnostic tests, 182, 185; early identification and intervention for, 185-186; iron chelator, possible effect of, 192; surgical management of, 188-190; types of, 181-183; useful resources for, 192-194
- heart, see *cardiac*
- heartburn, 84
- height, 81-83, 144-148, 158, 160-163, 165-167, 169-170, 174, 176, 248, 377, 383; adult height, estimates of, 146, 147, 148, 160; androgen use, effect on, 147, 169; birth weight, effect on, 146; caloric intake, effect on, 147; early or delayed puberty, effect on, treatment for, 147-148, 162, 163; height prediction based on bone maturation, 147-148; hormone deficiencies, effect on, 145-146; parental height, 146; short stature, 17, 19, 81, 130, 144, 145-147
- hematology, 5, 26, 42, 73, 96, 250, 304, 397; clinical monitoring of bone marrow failure, 49-52, see also *bone marrow*; management guidelines for bone marrow failure, 58-61 45-48, see also *bone marrow*; significance of clonal abnormalities, see *clones, cytogenetic clonal abnormalities*; supportive care, for severe marrow failure, 61-68; treatment options for bone marrow failure, 52-58, see also *bone marrow*
- hematopoietic growth factor, 223, 229, 238
- hematopoietic stem cell transplant, see *transplant*
- hemochromatosis, 93, 247, see also *iron overload*
- hemoglobin, 45, 54-55, 57, 60-62, 73, 149, 154, 224, 240, 388; as indicator for transplant, 224; effects of high altitude on, 61; fetal hemoglobin, 45, 154; glycosylated hemoglobin, 149, 154; monitoring of, 61; response to androgens, 54-55, 60; response to cytokines, 57; response to transfusions, 60-62

- hepatic, 56, 62-64, 66, 74, 87, 89, 97-98, 249, 369, 375-376, 387; adenomas, 54, 56, 87, 88, 287, 291; androgens, effect on liver, see *androgens*; chronic hepatic GvHD of liver, 91-92, 249; cirrhosis, see *cirrhosis*; fatty infiltration of the liver, 93; hepatic fibrosis, 62, 63, 65; hepatic sinusoids, 87-88; hepatitis, 63, 90, 91, 93, 237; hepatocellular carcinoma, see *cancer, liver (hepatocellular)*; hepatoma, see *cancer, liver (hepatocellular)*; HSCT late effects, liver complications of, 249; iron overload, see *iron overload*; liver biopsy, 56, 63, 88, 89, 90, 92, 93, 249, 253; liver enzymes, 66, 86, 87, 88, 90, 91, 92, 237, 369, 374, 376; liver function and function tests, 56, 88, 134, 228, 253; liver transaminases, 56, 88, 89; liver tumor, see *cancer, liver (hepatocellular)*; peliosis hepatis, 54, 87-88
- herbal remedies, 226; see also *vitamins, minerals, and herbal remedies*
- heterozygote, 8
- hip, dislocation, congenital, 54, 87-88
- human papillomavirus immunization, see *vaccinations/immunizations*
- humerus, 113
- hydrogen breath test, 79
- hyperglycemia, 154, 156, 171, 237
- hyperlipidemia, see *dyslipidemia*
- hypertension, 175, 223, 237, 256; androgen use, side effect of, 54; late effect of transplant, 237
- hypertransaminasemia, 88
- hypogenitalia, 19
- hypogonadism, see *gonads, gonadal function*
- hypopharynx, 210, 275, see also *head and neck squamous cell carcinoma*
- hypospadias, 164
- hypothalamus, 158, 162, 171
- hypothyroidism, see *thyroid*
- immunizations, see *vaccinations/immunizations*
- immunoglobulin, 216
- Individuals with Disabilities Education Act (IDEA), 185, 194-195, 267, 376
- infections, 18, 43, 53, 56-57, 67-68, 78, 80, 84, 91, 124, 140, 189, 192, 203,

- 212-213, 216, 223, 228, 236, 239, 241, 251, 264, 278, 298, 353, 369, 382, 390; adenovirus, 260; alternate donor HSCT, risks and timing of infections after, 235; bacterial, 55, 56, 215, 233; cytomegalovirus (CMV), 62, 215, 220, 237, 375; Epstein-Barr virus (EBV), 11, 272; fungal, 68, 80, 215, 374; gastrostomy tubes, local infection from, 68, 80, 215, 374; giardia antigen, 79; hepatitis, chronic viral, 91; herpes or herpes simplex virus (HSV), 214, 215; HIV, 85, 237; infectious disease prophylaxis post-HSCT, 235; opportunistic, 78, 79, 223, 236, 374; ova and parasites, 82; prevention strategies, 136, 216, 235; protozoal, 374; systemic, 221, 223; urinary tract, 78, 369; varicella zoster virus (VZV), 90, 215; viral, 53, 55, 215, 264, 374; yeast, 215, 235, 374; *Yersinia enterocolitica*, 64, 65
- infertility, see *fertility*
- insulin, 86, 132, 144, 150, 153-154, 156, 167, 170-172, 250, 257, 377, abnormal lipid profile associated with insulin resistance, 156; abnormal metabolism of, 144, 153-154, 156; insulin-like growth factor I, 148, 149, 158, 254; hyperinsulinemia, 155, 171; screening for insulin levels, 86, 149, 154, 250; treatment of diabetes with, 155
- insurance, problems, 225, 226; insurance approval prior to donor search, 229
- International Fanconi Anemia Registry (IFAR), 24, 42, 44, 47, 69-70, 96, 171, 175, 256, 295, 304, 316, 319, 327, 329
- in vitro* fertilization, 221, 240, 324, 337, 389
- iron deficiency, 44
- iron overload, 2, 14, 58, 62-66, 73, 90, 92-94, 98, 153, 169, 247, 249, 296, 375, 381; chelation therapy, 63-64, 94, 238; clinical complications of, 63-64; effect of chelator on auditory function, 192, 376; effect of on endocrine function, 153, 169; iron supplements, risk of, 93, 95; management of, 64-66, 296; post-transplant, assessment and treatment of, 246, 247, 249, 252, 253, 296; transfusions, effect of on, 2, 14, 58, 62, 64, 90, 92-93, 153, 169, 375, 381
- iron supplements, 226
- irradiated blood, 62
- IVS4, see *FANCC IVS4*
- jejunum, 20
- kidney, 76, 101, 226, 236, 249, 282, 287, 290, 315, 369-370, 379, 391, see also *renal system*; absent, horseshoe, hypoplastic or dysplastic, 19, 369

- laryngoscopy, 283
- larynx, 210, 271, 275, 278-279, see also *head and neck squamous cell carcinoma*
- late effects of transplant, see *transplant, late effects*
- learning disabilities, 183-185, 227, 341-342
- leukoplakia, 389
- lipids, see *dyslipidemia*,
- liver, see *hepatic*
- lungs, 84, 197
- macrocytic red cells or macrocytosis, 17, 44-45
- magnesium, 166, 280
- malabsorption, 82
- malignancy, see *cancer* or specific type of cancer
- mammography, 128-129, 299, 379
- medications, 4, 56, 67, 80, 85, 90, 94, 127, 133, 175, 181, 199, 228, 232, 235, 344, 366, 371-372, 376, 386; antibiotics, 55, 68, 84, 181, 192, 198, 206, 215, 216, 236, 376; delayed gastric emptying, possibly caused by, 78; diarrhea, possibly caused by, 79, 228, 231, 232, 233, 234, 282; hearing loss, ototoxic drugs that may cause, 181, 192, 376; hepatotoxic drugs, 90; polypharmacy, 371; that inhibit platelet function, 67, 95
- menopause, 14, 123, 129, 131-133, 135, 143, 164, 167, 298, 300, 375, 379-381; hormone replacement therapy, 132, 136, 148; health risks, 131-132, 380; premature, 14, 19, 123, 129, 131-132, 135, 164, 167, 246, 298, 300, 375, 379, 380
- menses, 381
- mesenchymal cells, 263-264, 266
- metabolic syndrome, 86, 151, 156, 167, 171
- metacarpal, 19, 103-106, 108, 110, 118
- microcephaly, 8, 101
- micrognathia, 213
- midline defect, 161
- minerals, see *vitamins, minerals, and herbal remedies*

- mosaicism, 13, 15, 18, 30-32, 52, 195, 290, 294, 298, 304, 317, 389
- mouth sores, 214, 231, 233
- mucositis, 280-281
- mutation, 1, 7, 12, 14-15, 18, 23, 27-28, 30-31, 33-34, 36, 41-42, 51, 69, 128, 140-141, 146, 164, 238, 261, 264-265, 273, 286, 292, 299, 305, 308, 311-312, 314-319, 321-331, 371, 388-389, 391; analysis, effect on height, 146; high-risk mutations, 16-17; null 16, 34, 35
- myelodysplasia, myelodysplastic syndrome (MDS), 14-18, 37-39, 43-53, 60-61, 198, 220-225, 228-230, 238, 298, 371, 373; clonal abnormalities, 37-39, 45, 50, 57, significance of, 17; hematological care for, 51; HSCT treatment for, 60-61; indication to test for FA, 17
- nails, 110
- nasogastric tube, 83, 85
- nasojejeunal tube, 83, 84
- nasopharynx, 210, 275
- National Comprehensive Cancer Network, 320
- National Institute on Deafness and Other Communication Disorders
Information Clearinghouse, 193
- National Marrow Donor Program (NMDP), 59, 222, 225, 228-229, 241, 390
- nausea, 74, 78-81, 134, 347, 363, 376
- neurological, 248, 341; neurocognitive issues, 381; neuropsychology
evaluation, 248
- neutropenia, 43, 45, 57, 64, 66-67, 192, 235, 241, 281, 390; neutropenic, 63, 211
- neutrophil count, 56-57, 224, 239, 382; absolute neutrophil count, 57, 224, 239, 382
- North American Survey (NAS), 288, 295
- novel hematopoietic stem cell treatment options, 259-267
- nutrition, 83, 94, 144, 147-148, 150, 169, 173, 249, 376, 398-399; diet, see *diet*; nutrition as therapy, 81-85; overweight, see *obesity*, *overweight*; post-HSCT nutritional issues, 91; supplemental nutrition, 83-85, 91, 95; underweight, see *underweight*
- obesity, 74, 85-86, 93, 97, 150-151, 154, 156, 174, overweight, 85-86; diet,

- see *diet*; eating disorder, 86; glucocorticoids and anticonvulsant therapy, effect on, 170; metabolic syndrome, see *metabolic syndrome*; nutrition, see *nutrition*; over-the-counter weight loss preparations, 88; sleep disorder or snoring related to, 86
- odynophagia, 210, 275
- oral cavity, 203, 209, 248, 271-273, 275, 278, 283, 293, 389, 391, see also *head and neck squamous cell carcinoma*
- oral dryness, 137, 233, 246, 248, 279, 282; pain, 210, 214- 215
- oropharynx, 210, 251, 272, 275, 284, 298, see also *head and neck squamous cell carcinoma*
- osteopenia, 165, 250, 375, 390, osteoporosis, 56, 131-132, 135, 144, 165, 168, 170, 177, 250, 375, 380-381, 386, 390; bone mineral density, 132, 141, 144, 149-150, 152, 165-168, 172, 178, 370; bone therapy, 166-167; dual energy absorptiometry (DXA) scan, 166, 375; Z-score, 165
- ova and parasites, 79
- ovarian, 7-8, 22, 128, 131-132, 135, 141, 163-164, 167, 169, 177, 299, 308, 319, 322-323, 330-332, 387; failure, 131-132, 136, 164, 167; function, 169-170, effect of anticonvulsant therapy on, 170; tissue cryopreservation, 131, 164
- oxidative stress, 94, 239, 266, 390
- oxymetholone, 56-58, 69
- pain, abdominal, 74, 78-79, 81, 91; eye pain, with GvHD, 238; gastroesophageal reflux or tracheoesophageal fistula, pain from, 76-77; intestinal stricture, pain with, 77; oral, with GvHD, 233; sedation and analgesia for invasive procedures, 63 189, 299, 364
- pancreas, 62, 91-92; pancreatic beta cell dysfunction, 153, 170-171; pancreatic insufficiency, 91
- pancytopenia, 72
- penis, 162, 164
- peptic disorders, see *gastrointestinal*
- phalanx, 18, 109-110, 392
- pituitary, 62, 144, 148, 157, 159, 161-162, 169, 171, 173, 175-176, 387
- platelets, 45, 53, 57-58, 60, 67, 88, 95, 129, 224, 226, 241, 262, 364, 384, 390

- pneumonia, 77, 249
- polydactyly, 109-110, 121, 391, pre-axial, 109-110, 391
- polypharmacy, 371, 391, 414, 417
- potassium, 234
- pregnancy, 13-14, 45, 76, 124, 129-130, 141, 164, 176, 250, 257, 307, 312, 318, 323-325, 353, 379; amniocentesis, 18, 324, 371; androgen use during, 129; discuss childbearing options pre-transplant, 129-130; complications, 130; reproductive options and family planning, 323
- preimplantation genetic diagnosis (PGD), 2-3, 13, 33, 221, 241, 311, 323-326, 332, 337-338, 371, 390
- psychosocial issues, 248, 296, 302, 333, 343; high-risk behaviors, 274, 302; recommendations for the physician, 349
- puberty, 123-124, 139, 144, 147, 159, 162-163, 170, 173, 274, 377, 379; breast buds, 123-124; delay, 124, 162-163; early onset, 162; relation to transplant, 147, 149, 169; treatment benefits for bone mineralization, 165-167
- pulmonary, 223, 237, 249, 253, 374, complications, 223, 374, post-transplant, 223, 274; function, 249, 253
- quality of life, 49, 61, 132, 160, 167, 215, 237, 245, 251, 258, 261, 303, 341, 363, 376, 381
- radial ray, 20, 377; abnormalities, 20, 377; carpectomy, 117; centralization, 115-117, 119; classification of radial deficiency, 111-112; external fixator, 117, 119; radial deviation of the hand, 111, 116-119; splint, 115-116, 118; stretching, 114, 115
- radiation, sensitivity to, 79; non-radiation imaging techniques, 79; pediatric and adult CT protocols, 79; total body irradiation, risks of, 14, 57-58, 60-62, 64, 73, 90, 92-94, 130, 162, 174, 177, 192, 201, 216, 223, 228-229, 238, 241, 269, 296, 299, 375, 381, 392
- reactive airway disease, 228
- red cells, 17, 53, 57-58, 62, 64, 384, androgen effect on, 53; iron overload, 62; macrocytosis, 44-45; transfusions of, 57-58; transfusions for uterine bleeding, 133
- reflux, 77, 80, 84, 167, 226, 369; esophageal, 167; gastroesophageal (GER), 77, 80, 84, 226; ureteral, 226
- renal system, anomalies, 76, 101, 102, 226, 246, 369, 370, 379;

hydronephrosis, 19, 369; hydroureter, 19; toxicity 94-95

ribs, 189

scaphoid, 114

school, education, 184-186, 302, 341-342, 381

scoliosis, 250, 257

seizures, 130, 232-233

Self Help for Hard of Hearing People, 193

Sertoli cell mass, 164

serum C-reactive protein, 79

sexually transmitted diseases, 124-125, 136, 274

short stature, see *height*

siblings of FA patients, 3-4, 30, 33-34, 44, 58, 191, 227, 302, 313, 317, 324, 332-333, 337-339, 342, 347, 351, 355, 367, 372; genotype/phenotype correlations between FA siblings, 33, 313-317; onset of bone marrow failure between FA siblings, 44, 372; psychosocial demands on, 4, 335, 337-339; psychosocial functioning of FA patients compared to healthy siblings, 355-356; test to rule out FA in, 30, 191, 367

sinuses, 228, sinusitis, 248

skeletal anomalies, 99

skin, see *dermatology*

smoking, cannabis (marijuana) 274; cigarettes, 298; second-hand smoke, 251, 271-272, 274, 283, 378

speech and language therapy, 186, 376

squamous cell carcinoma, see *cancer* or specific type of cancer

St. John's wort, 228

stroke, 73, 131

Sweet's syndrome, see *dermatology*

testes, 144, 162-164, 167, 382

thalassemia, 62-64, 73

thrombocytopenia, 43, 45, 57, 64, 67, 88, 129-130, 133, 141-142, 392

thumb, abnormalities of, 114; duplicated thumbs, 110; hypoplastic, floating

- (*pouce flottant*) or absent, 99, 103-104; opponensplasty, 104; pollicization, 104; triphalangeal, 19, 109-110
- thyroid, 62, 133, 144, 147, 156-158, 167, 169, 171-173, 177-178, 206, 208, 221, 250, 370, 381, 388; effect of anticonvulsant therapy or metaclopramide on, 170; hypoparathyroidism, 63, 169; hypothyroidism, 63, 124, 133, 144-147, 149, 156-158, 161-162, 167, 169-171, 246, 250, 374, 377, 388; post-HSCT, function, 169-170
- thyroxine-binding globulin (TBG, T4, FT4), 149, 156-58, 167, 253-54
- tobacco use, see *smoking*
- tracheoesophageal fistula, 75-76, 226, 392
- transaminitis, 249
- transfusions, effect on iron load, 62-66, 90, 92-94, 169, 238, 375, 381; family members as donors, 62, 375; for abnormal uterine bleeding, 133; HLA-typing and donor search before need for, 51, 58-59; menstrual suppression to decrease risk for transfusion prior to transplant, 133-135; platelet transfusions, 67; pregnancy, transfusions related to, 130
- transplant, 4, 13, 17-18, 47-48, 51-53, 57-62, 64, 67, 71, 74, 91, 98, 123, 129, 133-134, 141, 147, 149, 176-178, 199, 201, 220, 222-230, 235-242, 244-245, 247, 251-252, 255, 257-258, 262-264, 291, 295-297, 299-300, 325, 334, 337-339, 342, 346-347, 354-355, 358, 362, 364-366, 372-373, 375-376, 379-381, 383-389
- transplant, androgen use prior to, see *androgens*
- transplant, effect of clonal abnormalities, see *clones, cytogenetic clonal abnormalities*
- transplant, fertility, 123, 129, 135, 164, 231, 246, 373, 379
- transplant, grafts, 71, 106, 242; graft failure, 221-223, 236-237
- transplant, graft-versus-host disease (GvHD), 18, 53, 19, 55, 64, 91-92, 94, 101, 128, 136, 142, 181, 196, 200-202, 204, 206-207, 220, 222-223, 228, 232-233, 235-237, 240, 246-251, 255-256, 263-264, 271, 273, 283, 296-297, 299, 311, 380, 386-387; acute, 233; chronic, 233; concurrent medication, effect on, 227-228; immunosuppression, 232; infection risk, 235, 237, 251; ocular complications, see *vision*; prophylaxis, 235; risk of carcinoma from, 221-222, 237-238
- transplant, hematopoietic stem cell, 52-53, 60, 62, 64, 74, 91, 123, 141, 149, 219-255, 262, 376, see individual topics below

- transplant, immunizations post-transplant, see *vaccinations, immunizations*
- transplant, immunosuppression, 201, 220, 222, 232-233, 235, and immune reconstitution, 258
- transplant, late effects, 244-245; endocrine, 246, 250, 253; growth and development, 248, 254; hematology, 250, 252, 254; immunology, 251-252; malignancy risk, 251; metabolic syndrome, see *metabolic syndrome*; ocular complications, 248, see also *vision*; quality of life, 251
- transplant, matched sibling donor, 221-222; androgen and cytokine therapy prior to transplant, 238-239; cytoreductive regimens, overview and results of, 221-222
- transplant, organ function, effect on transplant, 246, 248-251
- transplant, post-transplant: long-term follow-up, 244-255
- transplant, radiation, 221-223; preparative regimen without radiation, 223
- transplant, selection of transplant center, 224-226, 373
- transplant, stem cell source, marrow, 219, 228-229; peripheral blood, 11, 14, 20, 28-29, 31-32, 39-40, 45-46, 48-51, 53, 133, 191, 223, 228, 230, 237, 240; umbilical cord blood, 222, 240-241, 323, 325, 390, 392
- transplant, transfusions prior to, see *transfusions*
- transplant, unrelated donor, 52, 59-61, 221-223, 228-229, 238, 372-373; alternatives to, 220, 223, 238-239, 336; donor search, insurance company approval, 51, 225-226, 229; donor search, selection, and timing of process, 59-60, 228-230, 373; eligibility for transplant, 226-230; indications for, 223-224; infection post-transplant, 251, 374; infectious disease prophylaxis, 235; initial assessment at transplant center, 224-227
- transposons, 264
- tumor, see *cancer* or specific type of cancer
- ulna, 111, 113, 115-119, 384; in centralization, 115-119; lengthening of, 111, 119-120
- underweight, 82, 86, 147-158; appetite stimulants, 85, 88, 96, 99; assessment of growth, 147-153; delayed gastric emptying, effect on, 77-78, 80-81, 85; duodenal atresia or stenosis, effect on, 75, 77; malabsorption, effect on, 82-83; medical causes of, 82-83; nutrition, see *nutrition*; nutritional causes of, 147-158; poor oral intake, 82-83; supplemental nutrition for, 83-85

- urinary tract, 75, 77-78, 369, 382; congenital anomalies, 16, 118, 250; ureteral reflux, 226
- uterus, 133-135, 164, 240-241, 389-390; menstrual bleeding, 123, 129, 133-135
- vaccinations, 125, 226, 251, immunizations, 226, 251-252, 374; hepatitis A and B, 90; HPV, 18, 124-127, 136, 238, 249, 251-252, 274, 298, 378-379, 381; post-transplant, 251-252, 374; influenza, 251, 374
- VACTERL, 75-76, 99, 101-102, 367; VACTERL-H, 20, 33, 101
- vaginal, 16, 125, 131-132, 138, 142-143, 379; dryness, 131-132, 138, 143
- virus, viral, see *infections*
- vision, 64, 248; cataracts, 19, 232, 234, 246, 248, 374, 381; keratoconjunctivitis sicca syndrome, 248; ocular complications post-transplant, 374; strabismus, 19; vision loss, side effect of deferoxamine, 64-65
- vitamins, 83, 90, 92-95, 226, minerals, 83, 390, and herbal remedies, 226; antioxidants, 93-94; calcium, 149, 151, 166, 254; fat-soluble vitamin levels, 90, 92; folate, 83; fortified fruit juice or other beverages, 92; magnesium, 166, 280; potassium, 234; supplements, 67, 83, 94-95, 151, 196, 200, 226, 228, 372; vitamin C, 93-95; vitamin D, 83, 149-151, 166, 196, 200, 250, 254; vitamins A and E, 92, 95, cancer risks of, 94; vitamins, effect of cholestasis on, 92; zinc, 83
- vomiting, 77, 84, 134
- vulvar cancer, see *gynecologic and fertility issues in females*
- weight, see *obesity, overweight; underweight; diet; nutrition; wheezing, 77*
- Wilms tumor, 16
- wrist, fusion, 119-120; radial deviation, 111, 113-119
- x-linked inheritance, 25, see also *genetic counseling*